Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report

Eva Van Bos¹*, Peter Dekuyper¹, Charlotte Gabriël², Marjan Waterloos¹, Anthony Van Baelen¹, Stefan Huybrechts¹, Filip Ameye¹, Antoon Lambrecht³, Christof Vulteke⁴,⁵ and Charlotte Soenens¹

Abstract

Background: Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy.

Case presentation: This report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy.

Conclusion: Low-dose-rate brachytherapy might be an etiology of small cell prostate cancer.

Keywords: Prostate cancer, Small cell carcinoma, Low-dose-rate brachytherapy, Ionizing radiotherapy, Chemotherapy, Immunotherapy

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
and immunohistochemical staining for NE markers such as CD56, chromogranin A (CgA), synaptophysin, and neuron-specific enolase [1, 2]. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is used for staging because up to 60% of the patients present with de novo metastatic disease [1, 4, 7]. Given the propensity for brain metastases, magnetic resonance imaging (MRI) of the brain should be considered [1].

The optimal treatment for patients with metastatic SCCP is not established, but chemotherapy regimens containing a taxane and platinum are often used. Immunotherapy is currently used for platinum-resistant extrapulmonary small cell carcinoma (EPSCC). Up to 60% of patients have tumor reduction with receipt of carboplatin, but the duration of the response is usually short [1, 3, 6, 8, 9]. Despite chemotherapy, SCCP has a poor prognosis, with a median survival of about 10–19 months [1, 4, 6].

Case reports have been published of SCCP following high-dose-rate brachytherapy [3]. To our knowledge, this report describes the first case of SCCP following low-dose-rate brachytherapy (LDR-BT) of the prostate for a low-risk prostate tumor.

Case presentation
In December 2011, a 73-year-old Caucasian man was admitted to our hospital with an elevated PSA of 8.59 ng/ml. His medical history consisted of cardiac stenting and pacemaker implantation. The finding of the digital rectal examination (DRE) was suspicious on the right base. His prostate volume on ultrasound was 37 ml, and his International Prostate Symptom Score was 6. Prostate biopsies showed a Gleason score of 3 + 3 = 6 prca of the right base and a Gleason score of 3 + 2 = 5 prca of the left apex. After negative staging with bone scintigraphy and CT of the abdomen, cT2aN0M0 prca was diagnosed. After a multidisciplinary discussion on the different therapeutic options, the patient decided to be treated with LDR-BT. Seventy-six seeds of $^{125}$I with a source activity of 0.373 mCi were implanted for a prescription dose of 145 Gy to the prostate. The first biochemical control after 4 months showed a significant drop of PSA to 0.75 ng/ml. Further oncological and clinical controls were reassuring, with a nadir PSA of 0.17 ng/ml (Table 1).

In August 2019, the patient experienced symptoms of dysuria, polyuria, and nocturia. DRE revealed an induration on the base of the prostate. The patient’s PSA concentration was 0.58 ng/ml, and the results of urinary culture and cytology were negative. The finding of cystoscopy was reassuring, except for a confined urethral stricture, which was easily dilated. MRI of the prostate could not be performed, because the patient had a non-MRI-compatible pacemaker. Prostate biopsies were scheduled. Four weeks later, a new DRE showed a manifestly increased mass. Anatomopathological examination revealed SCCP in all of the biopsies. Because pure SCCP is rare, a metastasis of SCC of the lung or prostatic invasion of SCC of the bladder was taken into account. The finding of chest CT was negative, and relook cystoscopy with random bladder biopsies under general anesthesia

| Date (iPSA) | PSA (ng/ml) |
|------------|-------------|
| 12/2011    | 8.59        |
| 08/2012    | 0.49        |
| 08/2013    | 0.31        |
| 09/2014    | 0.17        |
| 09/2015    | 0.25        |
| 09/2016    | 0.34        |
| 03/2017    | 0.33        |
| 09/2018    | 0.59        |
| 09/2019    | 0.44        |
was planned. The cystoscopy showed no abnormalities except for tumoral bulging of the bladder trigone. The patient underwent resection of the trigone and random biopsies. The random biopsies showed eosinophilic cystitis, whereas the resected trigone was diffusely infiltrated by SCC. Histological examination of the biopsies revealed a tumor forming sheets and nests of small epithelial cells with a high nuclear/ cytoplasmic ratio, prominent necrosis, and brisk mitotic activity. Crush artefact and nuclear molding typical of small cell cancer were present in all the biopsies. Immunohistochemistry showed expression of CgA and strong expression of CD56, nuclear expression of TTF-1, and dot-like expression of CKBR. The result of PSA staining was negative, and the finding of CK20 staining was negative, excluding Merkel cell carcinoma. CT of the abdomen showed multiple adenopathies in the iliac and obturator regions. Bone scintigraphy revealed multiple osteoblastic regions at the left ninth rib, sacrum, right ischiopubic region, and left os ilium (Fig. 1). FDG-PET/CT confirmed the presence of a tumor mass of the prostate with compression of the posterior bladder wall and positive lymph nodes in the iliac and obturator regions bilaterally (Fig. 1). The bone metastases did not capture FDG. Because of extreme lethargy and nausea, the patient had to be hospitalized and was monitored in the intensive care unit. Biochemical investigation showed severe hypotremia of 115 mmol/L, hypo-osmolality, and high urine osmolality. The patient was diagnosed with SIADH. His symptoms and laboratory test results recovered to normal with intravenous hypertonic saline infusion and fluid restriction.

The patient’s CT4N1M1b SCCP was discussed with a multidisciplinary tumor board. Chemotherapy consisting of carboplatin (area under the curve of 5mg/ml/min, day 1) and etoposide (100 mg/m2 on days 1–3) plus atezolizumab (1200 mg) was started for six cycles every 3 weeks. After three cycles, a partial response was seen that was maintained after six cycles. There was a clear and rapid clinical benefit after initiation of the therapy. Nevertheless, the patient had already developed progressive disease after the second course of maintenance atezolizumab.

**Discussion and conclusion**

This report presents the first case of pure SCCP following LDR-BT of the prostate for a low-risk prostate tumor. Pure SCCP is a very rare disorder in contrast to the more frequent prca with NE features (also called “aggressive-variant prca”), which emerges during the progression of prca.

Whereas the process of neuroendocrine differentiation (NED) after ADT is well known, only few cases of NED after radiotherapy have been described. Our patient developed pure SCCP almost 8 years after LDR-BT. Histological examination of the resected trigone showed all the features of small cell cancer.

NE cells are one of the three epithelial cell types in prostate tissue, accounting for < 1% [1, 10]. The physiological relevance of these cells remains controversial. The cells are androgen receptor–negative and do not proliferate themselves but induce proliferation in surrounding tumor cells by secreting peptide hormones and growth factors. Importantly, NE cells can dedifferentiate back to proliferating cells. By doing so, they contribute to tumor recurrence and proliferation [10]. Better understanding of this (de)differentiating process is needed.

Deng et al. studied the in vitro effect of ionizing radiation (IR) (40 Gy) on NED by using LNCaP prca cells (androgen receptor–positive prca cells) [10, 11]. Their main focus was cyclic AMP response–element binding protein (CREB) and activating transcription factor 2 (ATF2), which are known as activator and repressor, respectively, of NED. In 2008, they proved that IR induced NED by impairing the nuclear import of ATF2 and increasing the nuclear protein CREB [11]. In 2011, the same study group confirmed these findings in DU-145 and PC-3 cells, although to a lesser extent. To determine whether IR can induce NED in vivo, they conducted mouse xenograft models and used LNCaP cells that received 40 Gy of IR. Their findings were consistent with the in vitro results. They observed an increase in the CgA plasma level and concluded that CgA is the best biomarker for IR-induced NED because none of the nonirradiated mice had serum CgA elevation [10]. In 2014, Suarez et al. reported on the induction of NED by fractionated IR (40 Gy) in prca cells. They noticed two distinct phases: a radioresistant phase during the first 2 weeks, followed by a NED phase during 2 weeks. Again, increased activation of the transcription of CREB was observed. They successfully targeted CREB in vitro as a potential radiosensitizer and inhibitor of NED [12].

Our patient developed pure SCC in the prostate almost 8 year after initial treatment with LDR-BT. This may suggest a causal relationship between the development of SCCP and LDR-BT received at primary diagnosis, but some issues must be considered. First, the average time between diagnosis of adenocarcinoma and evolution to NE prca or SCCP reported in the literature ranges between 1 and 13 years, with a median of 20–80.4 months [13, 14]. Our patient, however, did not receive ADT in these 8 years, and in most of these studies, patients were initially treated with ADT. Second, if irradiation induces NED, one should possibly expect a much shorter duration of relapse, given the clinical behavior of SCCP. Third, the tumor might have developed independently from nonirradiated tissue. There is evidence that adenocarcinoma and SCCP have the same clonal origin. Hansel et al. showed a shared mutation in
Fig. 1  

a Tumoral prostate with invasion of the posterior bladder wall. The arrow points to the brachytherapy seeds in the prostate.  
b Right arrow shows positive lymph nodes in the iliac region and left arrow in the obturator region.  
c Upper arrow points to osteoblastic lesions in the rib, lower arrow in the sacrum and left os ileum on bone scintigraphy.
TP53, and Williamson et al. found a mutual rearrangement in ERG-TMPRSS2 [4, 15, 16].

The optimal way to treat men with metastatic CRPC and NED is not well established. Chemotherapy regimens consisting of a taxane and platinum agent are often used. Immunotherapy has also been used for platinum-resistant EPSCC. Responses are seen in up to 60% of patients, but responses are often of short duration [1, 3, 6, 8, 9]. Likewise, our patient showed a rapid onset of clinical benefit with a partial response after three cycles, but his disease had already progressed during the second course of maintenance therapy. Nevertheless, immunotherapy approaches should be tested within clinical trials, given the recent positive results reported by Horn et al. showing a significantly longer overall survival and progression-free survival in extensive stage small cell lung carcinoma in the chemotherapy and immunotherapy group compared with chemotherapy alone [8].

In conclusion, to our knowledge, this is the first case report suggesting LDR-BT received in the primary setting for pcrca might be an etiology for the development of SCCP. Although our patient showed a short duration of response to the therapy with checkpoint inhibition, clinical trials should investigate the added value of checkpoint inhibition to chemotherapy.

**Abbreviations**
ADT: Androgen deprivation therapy; ATF2: Activating transcription factor 2; CgA: Chromogranin A; CREB: cyclic AMP response element-binding protein; CRPC: Castration-resistant prostate carcinoma; DRE: Digital rectal examination; EPSCC: Extrapulmonary small cell carcinoma; FDG PET/CT: Fluorodeoxyglucose positron emission tomography/computed tomography; IR: Ionizing radiation; LDR-BT: Low-dose-rate brachytherapy; MRI: Magnetic resonance imaging; NE: Neuroendocrine; NED: Neuroendocrine differentiation; pcrca: Prostate cancer; PSA: Prostate-specific antigen; SCCP: Small cell carcinoma of the prostate; SIAD H: Syndrome of inappropriate antidiuretic hormone secretion

**Acknowledgements**
Not applicable.

**Authors’ contributions**
All authors contributed to the article. EVB wrote the article. CS, CV, and PD assisted with the writing and reviewed the article during the complete writing process. CG, AL, and CV were responsible for the case report parts describing the anatomopathology, radiotherapy, and oncology. MW, AVB, SH, and FA critically reviewed and revised the complete article. All authors read and approved the final manuscript.

**Funding**
Not applicable.

**Availability of data and materials**
Data sharing is not applicable to this article, because no datasets were generated or analyzed during the current study.

**Ethics approval and consent to participate**
This study was conducted in accordance with the fundamental principles of the Declaration of Helsinki.

**Consent for publication**
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Urology, AZ Maria Middelares, Buitenring-Sint-Denijs 30, 9000 Ghent, Belgium. 2Department of Pathology, AZ Maria Middelares, Ghent, Belgium. 3Department of Radiotherapy, AZ Groeninge, Kortrijk, Belgium. 4Department of Oncology, AZ Maria Middelares, Ghent, Belgium. 5Department of Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO), Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium.

Received: 14 June 2020 Accepted: 8 September 2020
Published online: 28 October 2020

**References**
1. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Cancer Netw. 2014;12:719–26.
2. Weprin S, Vanoever P. Small cell carcinoma of the prostate: a case report and brief review of the literature. Urol Case Rep. 2017;13:61–2.
3. Komiya A, et al. Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma. Oncol Lett. 2012;5:53–6.
4. Nadal R, Schweizer M, Kyvenko ON, Epstein JJ, Eisenberger MA. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11:213–9.
5. Bramer J, Lulla P, Lynch GR. Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate. Int J Clin Oncol. 2011;16:722–5.
6. Peverelli G, Grassi P. Pure small cell recurrent prostate cancer developing syndrome of inappropriate antidiuretic hormone secretion. Tumori. 2017;103:556–9.
7. Gregory DL, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extrapulmonary small-cell cancer. J Med Imaging Radiat Oncol. 2010;54:100–7.
8. Horn L, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.
9. Salhab M, Donahue M, Walsh W. Pembrozlimab for platinum refractory small cell carcinoma of the prostate: case report. Hematol Med Oncol. 2018;31:3.
10. Deng X, et al. Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res. 2011;1:834–44.
11. Deng X, et al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res. 2008;68:9663–70.
12. Suarez CD, Deng X, Hu CD. Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells. Am J Cancer Res. 2014;4:850–61.
13. Wang HT, et al. Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. J Clin Oncol. 2014;32:3983–90.
14. Brownback K, Renzulli J, DeLellis R, Myers J. Small-cell prostate carcinoma: a retrospective analysis of five newly reported cases. Indian J Urol. 2009;25(2): 259–63.
15. Hansel DE, et al. Shared T7PS3 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009;69:963–9.
16. Williamson SR, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24:1120–7.